Background
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential genes and sequences for elimination, including recombinogenic or mobile DNA and cryptic virulence genes, while preserving robust growth and protein production. Genome reduction also led to unanticipated beneficial properties, including high electroporation efficiency and accurate propagation of recombinant genes and plasmids that are unstable in other strains. Subsequent deletions and introduction of useful alleles produce strains suitable for many molecular biology applications. Recently, Scarab has built on the MDS™42 foundation strain, by creating the MDS™42 Meta LowMut strain. It improves the already low mutation rate of the MDS™42 foundation strain. The MDS™42 Meta LowMut strain has been engineered to greatly reduce error-prone repair, which reduces the mutation rate to almost zero, even under the most stressful conditions, thus ensuring the most accurate replication of your plasmid. In addition, its metabolism has been optimized to enable ULTRA high density fermentation ~300 OD600 in minimal media at the 10 liter scale, which in turn enables ULTRA high biotherapeutic yields, protein or plasmid.
Figures
Figure 1. MDS™42 Meta LowMut has the Lowest Mutation Rate Under Stress. Mutation rates of various strains under unstressed and stressful conditions were determined. Stress conditions include overproduction of GFP, overproduction of a toxic peptide from pSG-ORF238 and treatment with mitomycin-C. All measurements were made using the cycA fluctuation assay, error bars represent 95% confidence intervals for the average of 3 independent measurements. BL21(DE3) failed to grow in the presence of 0.1 μg/ml mitomycin-C. ANOVA revealed a significance of p < 0.0001. Pairwise t-tests were conducted for each strain under a given condition compared to the corresponding MDS™42_lowmut strain.
Figure 2: Non-Expressing Plasmid Mutations Accumulate rapidly in BL21(DE3), When a Toxic Methyltransferase is Overproduced. SinI methyltransferase was expressed from pSin32. Plasmids were isolated at various intervals and screened (by transformation in McrBC+ and McrBC- hosts) for mutations resulting in loss of function of the enzyme. Error bars represent 95% confidence intervals for the average of 3 independent measurements of mutant plasmid ratios. ANOVA revealed a significance of p < 0.005. Pairwise t-tests of each MDS™42_lowmut_mcrBC sample were done with the corresponding MDS™42 mcrBC and BL21(DE3) mcrBC sample, respectively. Starting from 10 hours, all MDS™42_lowmut_mcrBC samples differed significantly from the MDS™42 mcrBC (p < 0.01) or BL21(DE3) mcrBC (p < 0.005) samples.
Figure 3: Multiple Deletion Strains tolerate "deleterious” genes. A chimeric gene composed of VP60 of rabbit hemorrhagic disease virus fused to the B subunit of cholera toxin (CTX) was very unstable in E. coli. Individually, both genes were stable in E. coli HB101, C600 and DH10B, but pCTXVP60 carrying the fusion gene in the same hosts did not produce fusion protein and was recovered in low yields. All recovered plasmids contained mutations in the CTXVP60 open reading frame, virtually all resulting from IS insertions. In contrast, the recombinant plasmid was completely stable in MDS™; normal yields of plasmid DNA were obtained. Representative restriction patterns of pCTXVP60. (A) Plasmid DNA from MDS™42 was transformed and propagated in the indicated host, then digested with NcoI and EcoRI. A representative of each restriction pattern was purified and sequenced. M, molecular weight marker, 1 kbp ladder; 1, MDS™41, no insertion; 2, MDS™42, no insertion; 3, DH10B, IS10 insertion; 4, DH10B, IS10 insertion/deletion; 5, C600, IS5 insertion; 6, C600, IS1 insertion; 7, C600, IS1 insertion. (B) Relative position of the IS element insertion sites in the CTXVP60 reading frame determined for the five examples presented.
Figure 4: Plasmid stability in different host strains. Left: during four subcultures of pT-ITR, a plasmid with viral LTR segments; Lane 0, isolated plasmid DNA before subculture, lanes 1-4, successive subcultures. Plasmid DNA was digested with restriction enzymes and analyzed by agarose gel electrophoresis. KpnI cuts the plasmid at a single site, but in MG1655 two bands indicate a deletion in the plasmid. MscI cuts at two locations, but in MG1655 a third intermediate band confirms that the plasmid is deleted. Right: Stability of four variants of a Lentiviral expression plasmid in MDS™42 ΔrecA and Stbl3™ (Life Technologies), showing the proportion of transformants containing intact plasmids (Table 2 BioTechniques 43:466-470 (October 2007))(2).
Specifications
Kit Components MDS™42 Meta LowMut Electrocompetent Cell Kit pUC19 Control DNA (10 pg/µl) SOC Medium Genotypes MG1655 multiple-deletion strain (1) relA* Δrph ΔarpA ΔiclR ilvG+ ΔdinB ΔpolB ΔumuDC (2). Quality Control Transformation efficiency is tested using pUC19 control DNA, performed in duplicate. Transformed cells are plated on LB plates containing 50 μg/ml carbenicillin. Transformation efficiency is ≥1x108 cfu/μg DNA. Storage Conditions Store components at –80°C. Do not store cells in liquid nitrogen.
Related Products
White Glove IS Detection Kit
Support
Product Manuals MDS™42 Meta LowMut Chemically Competent Cell Kit Papers
- Pósfai G, et al., (2006) Emergent properties of reduced-genome Escherichia coli. Science 312:1044-6.
- Csörgő et al. (2012) Low-Mutation-Rate, Reduced-Genome Escherichia coli an Improved Host for Faithful Maintenance of Engineered Genetic Constructs Microbial Cell Factories, 11:11.
- Chacko S. Chakiath, CS & Esposito, D (2007): Improved recombinational stability of lentiviral expression vectors using reduced-genome Escherichia coli. BioTechniques 43:466-470.
Patents & Disclaimers
Products are sold for non-commercial use only, under Scarab Genomics limited use label license: Limited Label Use.Scarab is providing you with this Material subject to the non-transferable right to use the subject amount of the Material for your research at your academic institution. The Recipient agrees not to sell or otherwise transfer this Material, or anything derived or produced from the Material to a third party. NO RIGHTS ARE PROVIDED TO USE THE MATERIAL OR ANYTHING DERIVED OR PRODUCED FROM THE MATERIAL FOR COMMERCIAL PURPOSES. If the Recipient makes any changes to the chromosome of the Material that results in an invention in breach of this limited license, then Scarab will have a worldwide, exclusive, royalty-free license to such invention whether patentable or not. If the Recipient is not willing to accept the terms of this limited license, Scarab is willing to accept return of this product with a full refund, minus shipping and handling costs. For information on obtaining a license to this Material for purposes other than research, please contact Scarab’s Licensing Department. Scarab Genomics’ technology is covered by U.S. Pat. No. 6,989,265 and related foreign applications. Clean Genome® is a registered trademark of Scarab Genomics, LLC.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
不破坏细胞结构,同步动态侦测细胞有氧呼吸,糖酵解OCR/ECA(总或乳酸ECA);
i.过氧敏感荧光素(或pH敏感荧光素),Ex340-380/535/Em630-680nm,实时测量线粒体/胞内/胞外重要代谢指标,荧光素为非结构性结合可逆转改变;
ii.可同时或单个测量OCR/ECA或其他参数,不会做成浪费,可采用时间分辨荧光技术可加强系统信噪比
iii.通过两个加药口,可对检测细胞加入适当抑制剂/刺激实时监测细胞对不同毒素作用
缓慢的代谢在许多重要的方面保护了白血病细胞,使得它们能够更好的生存。研究小组还发现了一种针对这一独特代谢状态的实验性药物,并已开始检测它治疗这一疾病的效力。研究人员将相关结果发表在1月17日的《细胞干细胞》(CellStemCell)杂志上。
研究的通讯作者、罗彻斯特大学医学中心癌症中心教授CraigT.Jordan博士正在与一个药物制造商建立合作关系,在这一领域开展进一步的测试。实验室研究中的化合物已被用于临床试验。
Jordan说:“我们认为针对白血病干细胞代谢是一种独特的方法,有潜力广泛应用于几种形式的白血病。我们的研究工作令人感到兴奋,是因为我们鉴别出了一些现正开发用于临床的药物,我们希望其有巨大的潜力,可很快用于改善白血病患者的护理。”
主要研究员、Jordan实验室博士后EleniLagADInou说,当研究小组发现白血病干细胞的代谢与其他的肿瘤细胞如此不同之时,他们集中研究了这一过程的确切作用机制。
他们发现,白血病干细胞是通过一种称作氧化磷酸化的单一过程,在线粒体中生成了它们需要的所有能量。相比之下,其他的癌细胞和正常干细胞还依赖于第二种燃料来源——糖酵解来生成能量。
获得了这一新信息,随后研究人员探索了与氧化磷酸化相关的信号通路,以寻找致命弱点终止这一过程。他们发现一种称作BCL-2的重要基因表达增高,这对于白血病干细胞能量生成至关重要。
研究小组还了解了制药行业处于不同研发阶段的BCL-2抑制药物;Lagadinou和Jordan发现了两种这样的化合物,并在人类白血病样本中对它们进行了测试。研究结果表明,药物倾向性杀死不活跃的、代谢较慢的白血病干细胞。
众所周知,白血病细胞能够长时间休眠,在接受治疗后,可以突然发动另一轮的攻击。
Lagadinou说:“这种治疗有望靶向传统药物相对无法触及的,休眠白血病干细胞亚群。还有重要的一点需要指出,化合物不会损伤正常细胞,因为正常细胞能力利用另一条信号通路来生成能量。”
不会对健康细胞产生毒性,研究人员希望这些药物能够在缓解期靶向这一疾病,此时肃清残余白血病是极其重要的。
白血病,这种血癌可分为四种常见类型:急性髓系白血病(AML)、急性淋巴细胞白血病(ALL)、慢性粒细胞白血病(CML)和慢性淋巴细胞白血病(CLL)。AML在成人中最常见,且最难治疗,其部分原因是它影响了未成熟细胞。每年近5万新病例被确诊,约一半人死亡。
研究人员发现在过去的十年里,许多治疗并非旨在除去白血病根源——“白血病干细胞”,因此从未真正根除这一疾病。
Jordan说,事实上,即便是最现代的癌症治疗也是假设:所有的癌症代谢都依赖于糖酵解作为燃料来源。新研究发现氧化磷酸化是白血病干细胞的唯一燃料来源,这对提出新的改进治疗具有格外的意义(本文来自生物谷)
更多关于细胞学文章:http://www.hbzhan.com/st100044
希望能帮到你。
A.衰老的细胞新陈代谢速率加快
B.在衰老的细胞内有些酶的活性降低
C.衰老的细胞呼吸速率减慢
D.细胞膜通透性改变,使物质运输功能降低

